Literature DB >> 22546130

Lower mediastinal lymph node metastasis is an independent survival factor of Siewert type II and III adenocarcinomas in the gastroesophageal junction.

Masaki Nakamura1, Makoto Iwahashi, Mikihito Nakamori, Teiji Naka, Toshiyasu Ojima, Takeshi Iida, Masahiro Katsuda, Toshiaki Tsuji, Keiji Hayata, Shuuichi Mastumura, Hiroki Yamaue.   

Abstract

We examined clinicopathological features and surgical outcomes in patients with adenocarcinoma in the gastroesophageal junction (GEJ), while also analyzing the survival factors that have a prognostic impact. Between 1991 and 2009, 61 patients with tumors in the GEJ (Siewert type II and III) underwent primary surgical resection. Thirty of 61 patients had type II tumors (49.2%) and 31 had type III tumors (50.8%). The tumor size was larger in type III tumors than type II tumors (P = 0.0026). The overall 5-year survival rates in patients with type II tumors and type III tumors were 44.2 per cent and 41.4 per cent, respectively, with no significant differences (P = 0.1888). The independent survival factors were lower mediastinal lymph node metastasis (P = 0.0323) and a noncurative resection (P = 0.0442). The independent survival factors for patients who underwent curative resections were the tumor size (P = 0.0422), M category (P = 0.0489), and lower mediastinal lymph node metastasis (P = 0.0482). This study showed lower mediastinal lymph node metastasis to be an independent survival factor, and also suggested that lower mediastinal lymph node metastasis was associated with distant metastasis in patients with adenocarcinoma in the GEJ (Siewert type II and III). Therefore, the preoperative early detection of such metastasis is important to improve patient survival.

Entities:  

Mesh:

Year:  2012        PMID: 22546130

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  10 in total

1.  Comparison of the clinicopathological characteristics and the survival outcomes between the Siewert type II/III adenocarcinomas.

Authors:  Wei-Han Zhang; Xin-Zu Chen; Kai Liu; Kumar Anil; Kun Yang; Jia-Ping Chen; Zong-Guang Zhou; Jian-Kun Hu
Journal:  Med Oncol       Date:  2014-07-15       Impact factor: 3.064

2.  Lymph node metastasis and lymphadenectomy of resectable adenocarcinoma of the esophagogastric junction.

Authors:  Xin-Zu Chen; Wei-Han Zhang; Jian-Kun Hu
Journal:  Chin J Cancer Res       Date:  2014-06       Impact factor: 5.087

3.  Snail1 correlates with patient outcomes in E-cadherin-preserved gastroesophageal junction adenocarcinoma.

Authors:  H Dong; L Xie; C Tang; S Chen; Q Liu; Q Zhang; W Zheng; Z Zheng; H Zhang
Journal:  Clin Transl Oncol       Date:  2013-12-20       Impact factor: 3.405

4.  Curative resection for adenocarcinoma of the gastro-esophageal junction following neo-adjuvant chemotherapy-thoraco-abdominal vs. trans-abdominal approach.

Authors:  Naveena An Kumar; Ashwin Desouza; Manish S Bhandare; Jagan R Murugan; Gaurav Khandelwal; Vikram Chaudhari; Vikas Ostwal; Shailesh V Shrikhande
Journal:  Langenbecks Arch Surg       Date:  2020-11-26       Impact factor: 3.445

Review 5.  Siewert III adenocarcinoma: treatment update.

Authors:  Alberto Di Leo; Andrea Zanoni
Journal:  Updates Surg       Date:  2017-03-16

6.  Comparison of Efficacy Between Transabdominal and Transthoracic Surgical Approaches for Siewert Type II Adenocarcinoma of the Esophagogastric Junction: A Systematic Review and Meta-Analysis.

Authors:  Zonglin Li; Huaiwu Jiang; Jin Chen; Yifan Jiang; Yi Liu; Linxia Xu
Journal:  Front Oncol       Date:  2022-04-29       Impact factor: 5.738

7.  The length of proximal margin does not influence the prognosis of Siewert type II/III adenocarcinoma of esophagogastric junction after transhiatal curative gastrectomy.

Authors:  Fan Feng; Yangzi Tian; Guanghui Xu; Shushang Liu; Zhen Liu; Gaozan Zheng; Man Guo; Xiao Lian; Daiming Fan; Hongwei Zhang
Journal:  Springerplus       Date:  2016-05-11

8.  Optimal treatment for Siewert type II and III adenocarcinoma of the esophagogastric junction: A retrospective cohort study with long-term follow-up.

Authors:  Kei Hosoda; Keishi Yamashita; Hiromitsu Moriya; Hiroaki Mieno; Masahiko Watanabe
Journal:  World J Gastroenterol       Date:  2017-04-21       Impact factor: 5.742

9.  The metastasis-associated gene MTA3, a component of the Mi-2/NuRD transcriptional repression complex, predicts prognosis of gastroesophageal junction adenocarcinoma.

Authors:  Hongmei Dong; Hong Guo; Liangxi Xie; Geng Wang; Xueyun Zhong; Thaer Khoury; Dongfeng Tan; Hao Zhang
Journal:  PLoS One       Date:  2013-05-03       Impact factor: 3.240

10.  Solitary metastasis to a superior mediastinal lymph node after distal gastrectomy for gastric cancer: a case report.

Authors:  Naoki Kubo; Junichi Yoshizawa; Takaomi Hanaoka
Journal:  BMC Cancer       Date:  2018-06-04       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.